Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Status:	Completed
Conditions:	Diabetes, Diabetes
Therapuetic Areas:	Endocrinology
Healthy:	No
Age Range:	18 - Any
Updated:	1/12/2017
Start Date:	June 2003
End Date:	November 2004

NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy

This trial is conducted in the United States of America (USA). The aim of this trial is to
investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not
achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or
without basal insulin therapy.

Inclusion Criteria:

- Type 2 diabetes mellitus for at least 12 months

- HbA1c: 7.5-10.0%

- An antidiabetic regimen that has been stable for at least 3 months

- Able and willing to perform SMBG testing as per protocol

Exclusion Criteria:

- Use of any insulin preparations other than NPH or glargine within the past 6 months

- Pregnancy, breastfeeding, intention to become pregnant within the next 12 months, or
judged to be using inadequate contraceptive measures (adequate contraceptive measures
includes: sterilization, intrauterine devices, oral contraceptives, or consistent use
of barrier methods)

- Known or suspected allergy to trial product or agents related to trial product

We found this trial at

sites

Novo Nordisk Investigational Site

Houston, Texas 77030

from

Houston, TX